Teva settles with Catalent, Perrigo in inhaler patent suit

Catalent and Perrigo will be able to sell generic versions of Teva's ($TEVA) ProAir HFA inhaler starting in late 2016, resolving a patent dispute between the two parties. Teva had initially sued to block Catalent and Perrigo, saying the pair infringed four of its patents in their plans for a knock-off inhaler. Under the settlement, the two can sell a limited amount of inhalers from Dec. 19, 2016 until June 2018, at which point the restrictions expire.

Suggested Articles

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

After delisting from the New York Stock Exchange, WuXi AppTec has received regulatory approval to be listed in Shanghai.

Raxone is currently in a phase 3 study on DMD patients who are taking glucocorticoids.